The short interest data has been released for the June 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.
The June 15 short interest data have been compared with the previous figures, and for the selected stocks, short interest is mixed.
Pfizer Inc. (NYSE: PFE) saw its short interest increase to 73.77 million shares from the previous 62.91 million. In February, short interest spiked incredibly, and since that time it has slowly backed off. The highest short interest reading on the year was 207.4 million. Shares of Pfizer closed Wednesday at $34.23, within a 52-week trading range of $27.51 to $35.53.
Merck & Co. Inc. (NYSE: MRK) saw its short interest increase to 32.11 million shares from 31.49 million in the previous period. The current and previous readings are some of the highest in the past 52 weeks. Merck shares closed Wednesday at $58.24, in a 52-week trading range of $52.49 to $63.62.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest fell to 5.87 million shares. The level for the previous settlement date was 6.47 million. Shares of Teva closed Wednesday at $59.37, in a 52-week range of $47.36 to $68.75.
ALSO READ: Short Sellers Get More Selective on Big Biotech
Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest rise to 23.38 million shares from the previous reading of 22.12 million. The past few readings, including the current one, are the lowest short interest of the year. Bristol-Myers shares closed Wednesday at $66.81, within a 52-week trading range of $47.34 to $69.86.
AbbVie Inc.‘s (NYSE: ABBV) short interest decreased to 86.38 million shares from the previous level of 92.46 million. Short interest has backed off its highest level year to date; the highest reading in the past 52-weeks was 111.88 million. Shares of AbbVie closed Wednesday at $69.22, in a 52-week trading range of $51.37 to $70.76.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
